In Vivo Repair of a Protein Underlying a Neurological Disorder by Programmable RNA Editing.

Area of Science:

• Neuroscience
• Molecular Biology
• Genetics

Background:

• Programmable RNA editing offers a novel strategy for correcting genetic mutations.
• Its efficacy in repairing endogenous mutant RNA within complex tissues, such as the brain, remains largely unexplored.

Purpose of the Study:

• To investigate the efficiency of programmable RNA editing in repairing a specific mutation in the methyl CpG binding protein 2 (MECP2) gene.
• To assess the therapeutic potential of this approach for Rett syndrome, a neurodevelopmental disorder caused by MECP2 mutations.

Main Methods:

• Adeno-associated virus (AAV) vectors were engineered to deliver the hyperactive catalytic domain of adenosine deaminase acting on RNA 2 (HA2) and a guide RNA targeting MECP2.
• These vectors were administered via hippocampal injections into juvenile Mecp2317G>A mutant mice.
• RNA editing efficiency, protein restoration, and off-target effects were analyzed after one month.

Main Results:

• Significant recoding of Mecp2 RNA (50%) was achieved in multiple hippocampal neuronal populations.
• Restoration of MeCP2 protein localization to heterochromatin reached 50% of wild-type levels.
• Whole-transcriptome analysis revealed that off-target editing rates were generally low (≤30%).

Conclusions:

• Programmable RNA editing is effective in repairing endogenous MECP2 mutations in the mouse brain.
• This study validates the use of RNA editing as a viable therapeutic strategy for neurological diseases caused by specific mutations.
• The findings support further development of RNA editing for treating conditions like Rett syndrome.